At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Trials of Primary Excision Combined With Preoperative Neoadjuvant Therapy and Adjuvant Therapy Was Used as a First-line Comprehensive Therapy for Oligometastasis of Urothelial Carcinoma（UC）.
In Brief
A Phase 2 clinical trial evaluating primary focal resection plus lymph node dissection, Tislelizumab, and 1 other intervention for Bladder Urothelial Carcinoma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
treatment of primary focal resection plus lymph node dissection combined with chemotherapy and anti-programmed cell death 1(PD-1) for Oligometastasis of urothelial carcinoma.
Study Details
Timeline
Interventions
Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma
Tislelizumab IV infusion of 200 mg Q3W
GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks